Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Ran Chen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ran Chen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Pure Global's MedTech Guide: Mastering Brazil's ANVISA RDC 497/2021 for Your Device Registration and GMP Certification Update

3:32
 
Share
 

Manage episode 508311986 series 3684625
Content provided by Ran Chen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ran Chen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In this episode of LATAM MedTech Insights, we dissect the crucial updates to Brazil's medical device regulations, specifically ANVISA's RDC 497/2021 and the recent amendment RDC 850/2024. We explore how these resolutions have fundamentally changed the administrative process for obtaining and renewing the essential Brazilian Good Manufacturing Practice (B-GMP) certificate. We uncover why the recent extension of B-GMP validity from two to four years makes a flawless submission more critical than ever. We'll walk you through a real-world case study of a diagnostic device manufacturer that faced a three-month market lockout due to minor administrative errors in their renewal application, highlighting the costly pitfalls of navigating these new standardized procedures without expert local knowledge. Key questions answered in this episode: 1. What is the true impact of RDC 497/2021 on my existing Brazilian device registration? 2. How did the recent RDC 850/2024 amendment change the game for B-GMP certificate renewals? 3. What are the most common and costly administrative pitfalls when submitting documents to ANVISA's Solicita system? 4. Why is a simple document codification error now enough to get my entire submission rejected? 5. How far in advance should I begin my B-GMP renewal process to avoid market disruption? 6. What specific steps can I take to ensure my technical dossier is compliant with the latest requirements? 7. How can I turn these regulatory updates into a strategic advantage for my company in Brazil? At Pure Global, we transform regulatory complexity into market access. Our team of local experts, powered by advanced AI tools, offers end-to-end solutions for MedTech and IVD companies in over 30 markets, including Brazil. From initial strategy to post-market surveillance, we act as your local representative to ensure your products reach the market efficiently and remain compliant. Don't let administrative hurdles block your growth in Latin America. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.
  continue reading

48 episodes

Artwork
iconShare
 
Manage episode 508311986 series 3684625
Content provided by Ran Chen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ran Chen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In this episode of LATAM MedTech Insights, we dissect the crucial updates to Brazil's medical device regulations, specifically ANVISA's RDC 497/2021 and the recent amendment RDC 850/2024. We explore how these resolutions have fundamentally changed the administrative process for obtaining and renewing the essential Brazilian Good Manufacturing Practice (B-GMP) certificate. We uncover why the recent extension of B-GMP validity from two to four years makes a flawless submission more critical than ever. We'll walk you through a real-world case study of a diagnostic device manufacturer that faced a three-month market lockout due to minor administrative errors in their renewal application, highlighting the costly pitfalls of navigating these new standardized procedures without expert local knowledge. Key questions answered in this episode: 1. What is the true impact of RDC 497/2021 on my existing Brazilian device registration? 2. How did the recent RDC 850/2024 amendment change the game for B-GMP certificate renewals? 3. What are the most common and costly administrative pitfalls when submitting documents to ANVISA's Solicita system? 4. Why is a simple document codification error now enough to get my entire submission rejected? 5. How far in advance should I begin my B-GMP renewal process to avoid market disruption? 6. What specific steps can I take to ensure my technical dossier is compliant with the latest requirements? 7. How can I turn these regulatory updates into a strategic advantage for my company in Brazil? At Pure Global, we transform regulatory complexity into market access. Our team of local experts, powered by advanced AI tools, offers end-to-end solutions for MedTech and IVD companies in over 30 markets, including Brazil. From initial strategy to post-market surveillance, we act as your local representative to ensure your products reach the market efficiently and remain compliant. Don't let administrative hurdles block your growth in Latin America. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.
  continue reading

48 episodes

Tutti gli episodi

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play